Novogen drug acts on prostate cancer
Tuesday, 23 November, 2004
Novogen (ASX: NRT) subsidiary Marshall Edwards (LSE AIM: MSH, Nasdaq: MSHL) has reported that its lead drug phenoxodiol can slow down the progression of hormone refractory prostate cancer.
The results from a Phase Ib/IIa study of the drug in men with advanced metastatic disease were reported at the American Association of Cancer Research conference in Florida last week.
The dose response study showed that at the higher doses, the drug slowed the progression of disease and affected PSA levels over a period of 6-18 months, with no apparent toxicity, suggesting that the drug exerted an anti-tumour effect.
The company is planning a Phase IIb/IIIa multicentre international clinical trial to further test the drug in men with hormone refractory prostate cancer.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
